Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mometasone
Drug ID BADD_D01490
Description Mometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.
Indications and Usage The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
Marketing Status experimental
ATC Code D07AC13; D07XC03; R01AD09; R03BA07
DrugBank ID DB00764
KEGG ID D08227
MeSH ID D000068656
PubChem ID 441335
TTD Drug ID D03HYX
NDC Product Code 65162-891; 69238-2446
UNII 8HR4QJ6DW8
Synonyms Mometasone Furoate | Furoate, Mometasone | Nasonex | Mometasone Furoate Monohydrate | Furoate Monohydrate, Mometasone | Monohydrate, Mometasone Furoate | Asmanex Twisthaler | Twisthaler, Asmanex | Asmanex | Rinelon | Elocon | Sch 32088 | Sch-32088 | Sch32088 | Mometasone
Chemical Information
Molecular Formula C22H28Cl2O4
CAS Registry Number 105102-22-5
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis allergic22.04.04.003; 10.01.04.0030.000202%
Rhinorrhoea22.12.03.0210.002338%
Rosacea23.02.08.001--Not Available
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014--Not Available
Sinus congestion22.04.06.0010.000202%Not Available
Sinus headache22.12.03.022; 17.14.01.0020.000303%
Sinusitis11.01.13.005; 22.07.03.007--
Skin atrophy23.01.05.001--
Skin depigmentation23.05.02.002--Not Available
Skin discolouration23.03.03.005--Not Available
Skin striae23.01.05.002--Not Available
Sleep disorder19.02.04.0010.000131%Not Available
Sneezing22.12.03.0240.001312%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000131%Not Available
Swelling08.01.03.0150.000059%Not Available
Swelling face23.04.01.018; 10.01.05.018; 08.01.03.1000.000059%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000131%Not Available
Tachycardia02.03.02.0070.000089%Not Available
Telangiectasia24.03.03.003; 23.06.03.001--
Thirst08.01.09.021; 14.03.02.0070.000131%Not Available
Throat irritation07.05.05.037; 22.12.03.0290.000493%Not Available
Toothache07.09.06.0010.000131%
Tremor17.01.06.0020.000178%
Type I hypersensitivity10.01.03.0060.000131%Not Available
Ulcer08.03.06.0010.000059%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.000297%
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.000190%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene